Charles Schwab Investment Management Inc. Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Charles Schwab Investment Management Inc. increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,246,925 shares of the biopharmaceutical company's stock after purchasing an additional 79,182 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.05% of Catalyst Pharmaceuticals worth $26,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after buying an additional 33,888 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock worth $8,710,000 after acquiring an additional 50,888 shares during the period. Wellington Management Group LLP purchased a new stake in Catalyst Pharmaceuticals in the third quarter worth $1,185,000. Redhawk Wealth Advisors Inc. bought a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $1,273,000. Finally, Spire Wealth Management increased its position in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 13,429 shares during the period. 79.22% of the stock is owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In related news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Stock Up 4.6 %

Shares of NASDAQ:CPRX traded up $1.07 on Friday, hitting $24.23. 1,801,712 shares of the company traded hands, compared to its average volume of 1,059,747. The company has a market cap of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84. The stock has a 50 day simple moving average of $22.34 and a 200-day simple moving average of $21.58. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $24.64.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Bank of America restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Robert W. Baird upped their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $32.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.